US10765663B2 - Nutrition composition - Google Patents
Nutrition composition Download PDFInfo
- Publication number
- US10765663B2 US10765663B2 US14/834,880 US201514834880A US10765663B2 US 10765663 B2 US10765663 B2 US 10765663B2 US 201514834880 A US201514834880 A US 201514834880A US 10765663 B2 US10765663 B2 US 10765663B2
- Authority
- US
- United States
- Prior art keywords
- threonine
- tryptophan
- methionine
- food
- isoleucine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 85
- 235000016709 nutrition Nutrition 0.000 title description 29
- 230000035764 nutrition Effects 0.000 title description 28
- 150000001413 amino acids Chemical class 0.000 claims abstract description 191
- 230000037406 food intake Effects 0.000 claims abstract description 137
- 235000012631 food intake Nutrition 0.000 claims abstract description 100
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims abstract description 81
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 80
- 239000004473 Threonine Substances 0.000 claims abstract description 73
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 71
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims abstract description 61
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 61
- 229930182817 methionine Natural products 0.000 claims abstract description 61
- 230000001105 regulatory effect Effects 0.000 claims abstract description 53
- 206010020710 Hyperphagia Diseases 0.000 claims abstract description 34
- 235000020830 overeating Nutrition 0.000 claims abstract description 34
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 229940024606 amino acid Drugs 0.000 claims description 169
- 235000013305 food Nutrition 0.000 claims description 83
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 58
- 229960000310 isoleucine Drugs 0.000 claims description 58
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 45
- 235000012054 meals Nutrition 0.000 claims description 42
- 235000019789 appetite Nutrition 0.000 claims description 41
- 230000036528 appetite Effects 0.000 claims description 41
- 230000009467 reduction Effects 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 21
- 208000002720 Malnutrition Diseases 0.000 claims description 19
- 238000004806 packaging method and process Methods 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 235000000112 undernutrition Nutrition 0.000 claims description 15
- 230000003247 decreasing effect Effects 0.000 claims description 14
- 230000035882 stress Effects 0.000 claims description 12
- 230000006872 improvement Effects 0.000 claims description 10
- 101800001586 Ghrelin Proteins 0.000 claims description 8
- 102000012004 Ghrelin Human genes 0.000 claims description 8
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 claims description 8
- 238000011321 prophylaxis Methods 0.000 claims description 8
- 230000009471 action Effects 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 230000001788 irregular Effects 0.000 claims description 6
- 235000020905 low-protein-diet Nutrition 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 230000032683 aging Effects 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 235000005911 diet Nutrition 0.000 claims description 5
- 230000037213 diet Effects 0.000 claims description 5
- 230000028327 secretion Effects 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 208000014644 Brain disease Diseases 0.000 claims description 3
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 3
- 208000032274 Encephalopathy Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 208000019693 Lung disease Diseases 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 229940127089 cytotoxic agent Drugs 0.000 claims description 3
- 208000003532 hypothyroidism Diseases 0.000 claims description 3
- 230000002989 hypothyroidism Effects 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 208000019423 liver disease Diseases 0.000 claims description 3
- 210000004798 organs belonging to the digestive system Anatomy 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 51
- 206010061428 decreased appetite Diseases 0.000 abstract description 8
- 208000022531 anorexia Diseases 0.000 abstract description 6
- 230000007774 longterm Effects 0.000 abstract description 5
- 235000001014 amino acid Nutrition 0.000 description 161
- 229960002898 threonine Drugs 0.000 description 53
- 229960004452 methionine Drugs 0.000 description 51
- 229960004799 tryptophan Drugs 0.000 description 50
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 40
- 102000011632 Caseins Human genes 0.000 description 38
- 108010076119 Caseins Proteins 0.000 description 38
- 239000005018 casein Substances 0.000 description 35
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 35
- 235000021240 caseins Nutrition 0.000 description 35
- 229960004295 valine Drugs 0.000 description 29
- 239000008187 granular material Substances 0.000 description 25
- 235000002639 sodium chloride Nutrition 0.000 description 25
- 230000037396 body weight Effects 0.000 description 21
- 150000003839 salts Chemical class 0.000 description 20
- -1 antibiotic Substances 0.000 description 19
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 239000004474 valine Substances 0.000 description 18
- 235000020776 essential amino acid Nutrition 0.000 description 15
- 239000003797 essential amino acid Substances 0.000 description 15
- 150000002632 lipids Chemical class 0.000 description 14
- 229930182844 L-isoleucine Natural products 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 13
- 125000003275 alpha amino acid group Chemical group 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 10
- 229930195722 L-methionine Natural products 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 239000003925 fat Substances 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
- 208000008589 Obesity Diseases 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 235000020824 obesity Nutrition 0.000 description 6
- 235000014347 soups Nutrition 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 5
- 241000251468 Actinopterygii Species 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 208000003286 Protein-Energy Malnutrition Diseases 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 229930003316 Vitamin D Natural products 0.000 description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 4
- 240000008042 Zea mays Species 0.000 description 4
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 235000005822 corn Nutrition 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 229940099112 cornstarch Drugs 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 229940127557 pharmaceutical product Drugs 0.000 description 4
- 229960005190 phenylalanine Drugs 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 235000020826 protein-energy malnutrition Nutrition 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 235000013311 vegetables Nutrition 0.000 description 4
- 235000019155 vitamin A Nutrition 0.000 description 4
- 239000011719 vitamin A Substances 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 235000019166 vitamin D Nutrition 0.000 description 4
- 239000011710 vitamin D Substances 0.000 description 4
- 150000003710 vitamin D derivatives Chemical class 0.000 description 4
- 229940045997 vitamin a Drugs 0.000 description 4
- 229940046008 vitamin d Drugs 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 230000006229 amino acid addition Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000013325 dietary fiber Nutrition 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000005686 eating Nutrition 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000002864 food coloring agent Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 229960002885 histidine Drugs 0.000 description 3
- 230000013632 homeostatic process Effects 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 229960003284 iron Drugs 0.000 description 3
- 235000015110 jellies Nutrition 0.000 description 3
- 239000008274 jelly Substances 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Chemical class 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 235000012046 side dish Nutrition 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 239000011691 vitamin B1 Substances 0.000 description 3
- 239000011716 vitamin B2 Substances 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 239000004395 L-leucine Substances 0.000 description 2
- 235000019454 L-leucine Nutrition 0.000 description 2
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 210000000918 epididymis Anatomy 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 229960005191 ferric oxide Drugs 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960000299 mazindol Drugs 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000037023 motor activity Effects 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 235000008729 phenylalanine Nutrition 0.000 description 2
- 235000012015 potatoes Nutrition 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 230000036186 satiety Effects 0.000 description 2
- 235000019627 satiety Nutrition 0.000 description 2
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- LBXRPPWPQUZKBO-DKWTVANSSA-N (2s)-2-aminobutanedioic acid;hydrate Chemical compound O.OC(=O)[C@@H](N)CC(O)=O LBXRPPWPQUZKBO-DKWTVANSSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WLDHEUZGFKACJH-ZRUFZDNISA-K Amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1\N=N\C1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-ZRUFZDNISA-K 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 235000000832 Ayote Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 240000004244 Cucurbita moschata Species 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 108010028690 Fish Proteins Proteins 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 244000141009 Hypericum perforatum Species 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 239000004158 L-cystine Substances 0.000 description 1
- 235000019393 L-cystine Nutrition 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010070551 Meat Proteins Proteins 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241000238413 Octopus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000004283 Sodium sorbate Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 235000021407 appetite control Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 235000021205 intention to eat Nutrition 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940023462 paste product Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 235000015136 pumpkin Nutrition 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 description 1
- 235000019250 sodium sorbate Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000008371 vanilla flavor Substances 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/66—Proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/0632—Methionine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/0648—Threonine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/065—Tryptophan
Definitions
- the present invention relates to a food intake regulating agent containing 3 kinds of amino acids: threonine, methionine and tryptophan. More particularly, the present invention relates to a food intake regulating agent useful for the prophylaxis or improvement of undernutrition due to decreased appetite, lifestyle-related diseases due to overeating and the like.
- Obesity is developed by a disturbed balance of the above-mentioned homeostasis and calorie consumption, and produces many patients with lifestyle-related diseases such as hypertension, diabetes, hyperlipidemia and the like and people at risk thereof.
- Food consumption is increasing on a global scale, the obese individuals are still increasing, and prophylaxis or improvement of obesity has been desired.
- mazindol in amphetamines As a substance that regulates, particularly suppresses, food intake, mazindol in amphetamines is put to practical use as a pharmaceutical product. However, the use thereof is limited to highly obese individuals in view of the direct action of mazindol on the central nervous system and the risk of addiction, dependency and the like. Thus, a safe product that suppresses overeating and prevents obesity has been desired.
- cancer patients patients in an undernutrition state from anorexia due to the side effects of anti-cancer agents and the like, who cannot ingest sufficient nutrition, patients showing insufficient oral ingestion due to anorexia and stress caused by a disease and the like, the above-mentioned elderly people with unsatisfactory nutrition condition and the like may fall under Protein-Energy Malnutrition (PEM) which is undernutrition associated with lack of energy, thus problematically progressing into exacerbated nutrition conditions.
- PEM Protein-Energy Malnutrition
- An appetite control agent containing St. John's wort and an amino acid composed of at least one kind from tryptophan, phenylalanine, arginine, glutamine, histidine, methionine and tyrosine is described (See JP-A-2006-22072).
- the present invention aims to provide a food intake regulating agent which improves anorexia and overeating and is safe for ingestion for a long term.
- the present inventors have conducted intensive studies in view of the above-mentioned problems and found that a composition containing threonine, methionine and tryptophan, and the composition further containing isoleucine and/or valine have a food intake promoting action and a food intake suppressive action in combination, and can regulate food intake.
- composition as described above further comprising isoleucine.
- composition as described above, wherein the weight ratio of tryptophan, threonine, methionine and isoleucine is 1:0.5-12:0.2-10:0.5-12.
- composition as described above, wherein the weight ratio of tryptophan, threonine, methionine, isoleucine and valine is 1:0.5-12:0.2-10:0.5-12:0.5-15.
- composition as described above which is in a unit packaging form for one meal and comprises, in the unit, not less than 0.06 g of amino acid as an amount to be ingested for one meal as an active ingredient.
- composition as described above which is for the prophylaxis or improvement of reduction in appetite or an undernutrition state due to reduction in appetite.
- the reduction in appetite is caused by one or more kinds selected from aging, cancer, inflammation, decreased function of digestive organ, cardiac failure, renopathy, hepatic diseases, autoimmune disorder, lung disease, hypothyroidism, encephalopathy, anorexia nervosa, depression, dementia, Alzheimer's disease, chemotherapeutic agent, antibiotic, therapeutic agent for diabetes, trauma after surgery, lack of g
- composition as described above wherein the overeating is caused by psychological stress, physical stress, bulimia nervosa, depression, irregular lifestyle habit or low-protein diet.
- the body can be maintained in a normal state by controlling food intake by decreasing or promoting appetite according to the condition of the body by only ingesting at least 3 kinds of amino acids of tryptophan, threonine and methionine.
- amino acids are the active ingredients, food intake can be safely regulated by administration thereof for a long term; obesity and undernutrition can be improved; and QOL can be increased.
- food ingestion frequency and amount thereof particularly in elderly people can be improved to increase the ingestion amounts of energy, protein, lipid, vitamin and the like.
- ingestion of the food in the first group (fish, meat, egg, bean, soybean product etc.) in the six basic foods increases, and the body weight can be increased.
- FIG. 1 shows an average food intake per day at 2 weeks after feed exchange.
- FIG. 2 shows an average food intake per day at 2 weeks after feed exchange. * shows a significant difference (p ⁇ 0.05) as compared to 5AA.
- FIG. 3 shows food intake in the dark period for 2 hr before and after administration. ** shows a significant difference (p ⁇ 0.01) as compared to before administration, ⁇ shows a significant difference (p ⁇ 0.01) as compared to EAA.
- FIG. 4 shows body weight profile in 2 weeks of a blend feed test.
- ⁇ shows a significant difference (p ⁇ 0.05) as compared to 1% weight casein food group, and ⁇ shows a significant difference (p ⁇ 0.01) as compared to 1% weight casein food group.
- FIG. 5 shows food intake profile in the dark period.
- ⁇ shows a significant difference (p ⁇ 0.05) as compared to 1% weight casein food group, and ⁇ shows a significant difference (p ⁇ 0.01) as compared to 1% weight casein food group.
- FIG. 6 shows food intake profile in the dark period for 2 hr at 8 days after the start of a blend feed test (3 examples for each group).
- A, B, C 20 wt % casein food group
- D, E, F 1 wt % casein food group
- G, H, I 5AA food group.
- FIG. 7 shows satiety degree in the dark period for 12 hr at 3 days before, 5 days after, and 8 days after the start of a blend feed test.
- ⁇ shows a significant difference (p ⁇ 0.05) as compared to 1% weight casein food group.
- FIG. 8 shows body weight and each organ weight after 2 weeks of a blend feed test.
- A body weight
- B liver weight
- C epididymis fat weight
- D gastrocnemius muscle weight.
- ⁇ shows a significant difference (p ⁇ 0.05) as compared to 1% weight casein food group
- ⁇ shows a significant difference (p ⁇ 0.01) as compared to 1% weight casein food group.
- the present invention relates to a food intake regulating agent comprising at least 3 kinds of amino acids: (1) tryptophan, (2) threonine and (3) methionine.
- the food intake regulating agent of the present invention may further contain 4 or 5 kinds including (4) isoleucine or (4) isoleucine and (5) valine. Particularly, 5 kinds of amino acids of tryptophan, threonine, methionine, isoleucine and valine are preferably contained as active ingredients (hereinafter food intake regulating agents containing (1)-(3), (1)-(4) or (1)-(5) as active ingredients are sometimes to be generically abbreviated as the food intake regulating agent of the present invention).
- amino acids of the above-mentioned (1)-(5) to be used in the present invention may be any of an L-form, a D-form and a DL-form, with preference given to L-form.
- amino acids of the above-mentioned (1)-(5) to be used in the present invention may be in the form of a salt, and the amino acid is a concept also including a salt.
- Examples of the salt of the amino acids of (1)-(5) include acid addition salt, metal salt, ammonium salt, organic amine addition salt, amino acid addition salt and the like.
- the acid addition salt examples include inorganic acid salts such as hydrochloride, sulfate, nitrate, phosphate and the like, organic acid salts such as acetate, maleate, fumarate, citrate, malate, lactate, ⁇ -ketoglutarate, gluconate, caprylate and the like.
- metal salt examples include alkali metal salts such as sodium salt, potassium salt and the like, alkaline earth metal salts such as magnesium salt, calcium salt and the like, aluminum salt, zinc salt and the like.
- ammonium salt examples include salts such as ammonium, tetramethylammonium and the like.
- amino acid addition salt examples include salts with glycine, phenylalanine, lysine, aspartic acid, glutamic acid and the like.
- the salt of the amino acids of (1)-(5) may be a hydrate (hydrate salt), and examples of the hydrate include 1-6 hydrates and the like.
- amino acids of (1)-(5) of the present invention may be produced by any production method such as protein hydrolysis method, chemical synthesis method, enzyme method, fermentation method and the like, or commercially available products can also be used.
- amino acids of (1)-(5) of the present invention can also be obtained by enzymatically hydrolyzing natural proteins having the amino acid sequence thereof.
- the “regulation of food intake” means regulation of food intake by enhancing or decreasing the appetite for a long or short term. That is, it is a concept encompassing maintaining the body in a healthy condition by promotion or suppression of food intake by enhancing the appetite of a subject or a target animal having a reduced appetite and decreasing the appetite of a subject and the like showing an enhanced appetite.
- BMI Body Mass Index
- Promotion of food intake is a concept encompassing bringing decreased amounts of meal and feed or intake calorie to normal values, and further, increasing the values to a level suitable for curing the disease.
- Suppression of food intake is a concept encompassing bringing excess amounts of meal and feed or intake calorie to normal values, and further, decreasing the values to a level suitable for curing the disease.
- the normal value is determined based on the age, sex, body height, basal metabolism, amount of motor activity and the like. For example, the above-mentioned amounts of meal and feed or intake calorie capable of maintaining the ideal body weight are considered to be normal values.
- the food intake regulating agent of the present invention can enhance food intake and is used as a food intake enhancer, and is effective for the prophylaxis or improvement of reduction of appetite and undernutrition due to reduction of appetite.
- the improvement is a concept encompassing bringing a decreased appetite and undernutrition to a normal level, and further, prevention of progression (exacerbation) of diseases.
- Examples of the reduction of appetite include reduction of appetite due to aging, cancer, inflammation, decreased function of digestive organ, cardiac failure, renopathy, hepatic disease, autoimmune disorder, lung disease, hypothyroidism, encephalopathy, anorexia nervosa, depression, dementia, Alzheimer's disease, drug administration of anti-cancer agent, chemotherapeutic agent, antibiotic, therapeutic agent for diabetes and the like, and reduction of appetite in the subjects and target animals affected with trauma after surgery and the like.
- ghrelin which is a food intake promoting peptide produced in the periphery and having an important action on the regulation of energy metabolism such as promotion of food intake, body weight increase, regulation of gastrointestinal function and the like and insufficient action of ghrelin can be mentioned.
- the food intake regulating agent of the present invention is also preferably used for undernutrition, particularly Protein-Energy Malnutrition (PEM) caused by lack of protein and lack of energy occurring in combination.
- undernutrition refers to a state where nutrients in amounts necessary for a healthy life have not been ingested.
- the food intake regulating agent of the present invention is preferably used for reduction of appetite due to aging (reduction of appetite in elderly people), reduction of appetite in cancer patients, reduction of appetite due to anti-cancer agent treatment, reduction of appetite due to lack of ghrelin secretion or lack of ghrelin action, reduction of appetite due to low-protein diet and reduction of appetite due to undernutrition resulting therefrom.
- Reduction of appetite due to aging means a decrease in the frequency and amount of food intake.
- the food intake regulating agent of the present invention is also preferably used for body weight decrease due to the above-mentioned reduction of appetite.
- the food intake regulating agent of the present invention When the food intake regulating agent of the present invention is used as a food intake enhancing agent, at least the amino acids (1)-(3) of the present invention need to be contained, and the amino acids of (1)-(4) or (1)-(5) are preferably contained.
- the food intake regulating agent of the present invention can suppress food intake and used as a food intake inhibitor. It is effective for the prophylaxis or improvement of overeating and lifestyle-related diseases due to overeating.
- improvement is a concept encompassing bringing promoted appetite and overeating to a normal level, and further, preventing progression (exacerbation) of diseases.
- overeating examples include psychological stress, physical stress, low-protein diet, bulimia nervosa, depression, and overeating due to irregular lifestyle habit.
- the food intake regulating agent of the present invention When the food intake regulating agent of the present invention is used as a food intake inhibitor, at least the amino acids (1)-(3) of the present invention need to be contained, and the amino acid of (4) or (5) or (4) and (5) are preferably contained.
- the food intake regulating agent of the present invention means pharmaceutical products used for “regulating food intake”, a composition similar to a pharmaceutical product or functional food having a particular function and taken for the purpose of maintaining health and the like, such as health supplements, foods with health claims, supplements and the like.
- the food intake regulating agent of the present invention can be applied to human, animals other than human [for example, mammals other than human (domestic animals and pet animals such as swine, bovine, horse, canine and the like), birds (poultry and pet animals such as turkey, chicken and the like)] and the like.
- the weight ratio of tryptophan, threonine and methionine is generally 1:0.5-12:0.2-10, preferably 1:1-9:0.5-8, more preferably 1:2-6:1-5.
- the weight ratio of tryptophan, threonine, methionine and isoleucine is generally 1:0.5-12:0.2-10:0.5-12, preferably 1:1-9:0.5-8:1-9, more preferably 1:2-6:1-5:2-6.
- the weight ratio of tryptophan, threonine, methionine, isoleucine and valine is generally 1:0.5-12:0.2-10:0.5-12:0.5-15, preferably 1:1-9:0.5-8:1-9:1.5-10, more preferably 1:2-6:1-5:2-6:3-7.
- the content of each amino acid in the food intake regulating agent of the present invention is as follows.
- the weight (%) of each amino acid in the containing amino acids is
- the weight (%) of each amino acid in the contained amino acids is
- amino acid means a free amino acid, and does not include constituent amino acids in protein and peptide.
- the dose of the food intake regulating agent of the present invention varies depending on the age, sex, body weight, target disease, symptom, and dosage form, it is generally within the range of 60 mg-23 g, preferably 100 mg-20 g, more preferably 500 mg-15 g, further preferably 500 mg-5 g, particularly preferably 500 mg-2 g, in total of the amino acids of (1)-(3) for an adult (e.g., body weight 60 kg) per day, which is administered once to several times a day.
- the dose of the food intake regulating agent of the present invention is generally within the range of 60 mg-23 g, preferably 100 mg-20 g, more preferably 500 mg-15 g, further preferably 500 mg-5 g, particularly preferably 500 mg-2 g, in total of the amino acids of (1)-(4) for an adult per day, which is administered once to several times a day.
- the dose of the food intake regulating agent of the present invention is generally within the range of 60 mg-23 g, preferably 100 mg-20 g, more preferably 500 mg-15 g, further preferably 500 mg-5 g, particularly preferably 500 mg-2 g, in total of the amino acids of (1)-(5) for an adult per day, which is administered once to several times a day.
- the dose of (1) is generally within the range of 10 mg-9 g, preferably 20 mg-6 g, more preferably 80 mg-5 g, for an adult per day. A range of 90 mg-1 g is particularly preferable.
- the dose of (2) is generally within the range of 30 mg-20 g, preferably 60 mg-18 g, more preferably 250 mg-15 g, for an adult per day. A range of 250 mg-1 g is particularly preferable.
- the dose of (3) is generally within the range of 20 mg-18 g, preferably 40 mg-15 g, more preferably 170 mg-12 g, for an adult per day. A range of 180 mg-1 g is particularly preferable.
- the dose of (4) is generally within the range of 0 mg-20 g, preferably 60 mg-18 g, more preferably 250 mg-15 g, for an adult per day. A range of 300 mg-1 g is particularly preferable.
- the dose of (5) is generally within the range of 0 mg-20 g, preferably 100 mg-18 g, more preferably 300 mg-18 g, further preferably 400 mg-16 g, for an adult per day. A range of 500 mg-1 g is particularly preferable.
- the above-mentioned amount for an adult per one time can be appropriately changed in consideration of the body conditions such as sex, age, disease and the like.
- the above-mentioned amount per day can be administered once or divided in several portions.
- the dosing period is not particularly limited, and the agent can be administered for a long term since the ingredient is derived from amino acid.
- binders such as tragacanth, gum arabic, cornstarch and gelatin, polymerpolyvinylpyrrolidone and the like; excipients such as cellulose (microcrystalline cellulose, crystalline cellulose, hydroxypropylcellulose and the like) and a derivative thereof; swelling agents such as cornstarch, pregelatinized starch, alginic acid, and dextrin; lubricants such as magnesium stearate; flowability improver such as fine silicon dioxide, and methylcellulose; lubricants such as glycerol acid ester, talc, polyethylene glycol 6000 and the like; thickeners such as sodium carboxymethylcellulose, carboxyvinyl polymer, xanthan gum, gelatin and the like; sweetening agents such as sucrose, lactose and aspartam; flavors such as peppermint, vanilla flavor and cherry or orange; emulsifiers such as monoglyceride, poly
- a liquid carrier such as fats and oils can be further added to the above-mentioned type of materials.
- an aqueous solution of hydroxylphenylmethylcellulose is used as a coating pre-treatment agent, and an aqueous solution of hydroxypropylmethylcellulosephthalate and an aqueous solution of polyacetin are used as coating agents to produce an enteric preparation according to a conventional method.
- a solution containing the amino acids of (1)-(3) can be sprayed nasally, administered as an injection and the like.
- the amino acids of (1)-(3) may be dispersed in various bases and formulated according to a conventional method.
- Additives such as emulsifier and emulsion stabilizers such as ⁇ -monoglycerylether, lecithin, sorbitan fatty acid ester, dextrin fatty acid ester, fatty acid monoglyceride, fatty acid metal salt, magnesium sulfate and the like, aromatic, preservative, dye, thickener, antioxidant, UV protective agent, various efficacy agents such as wound healing agent, anti-inflammatory agent, moisturizer and the like and water may be added.
- emulsifier and emulsion stabilizers such as ⁇ -monoglycerylether, lecithin, sorbitan fatty acid ester, dextrin fatty acid ester, fatty acid monoglyceride, fatty acid metal salt, magnesium sulfate and the like, aromatic, preservative, dye, thickener, antioxidant, UV protective agent, various efficacy agents such as wound healing agent, anti-inflammatory agent, moisturizer and the like and water may be added.
- the pharmaceutical product in the present invention may be the food intake regulating agent itself of the present invention, or may also contain other additive and the like.
- the food intake regulating agent of the present invention When used as a food, it means a health food ingested by taking note of the particular function of the present invention, as well as a food for specified health uses and a food with nutrient function claims as defined in the food with health claims system, and further includes dietary supplements. While the amount of the amino acid contained in a food is not particularly limited, the amount to be drunk or eaten per day is preferably set to fall within a range similar to that of the above-mentioned dose of the food intake regulating agent of the present invention. The form of the food intake regulating agent of the present invention as a food with health claims is not particularly limited.
- the food in the present invention may be in a unit intake form for one meal containing the amino acids of (1)-(3), (1)-(4) or (1)-(5) and the like, the form of a bottle and the like filled with the amount to be ingested per meal of drinks of suspended or dissolved amino acids mentioned above, and the like.
- the dose per meal may be a daily dose mentioned above.
- a food or drink for regulating food intake which is in a unit packaging form for one meal, and contains not less than 0.06 g of 3 kinds of amino acids of tryptophan, threonine and methionine in total in the unit, wherein the weight ratio of tryptophan, threonine and methionine is 1:0.5-12:0.2-10, is also one embodiment of the present invention.
- the above-mentioned food or drink which is free of an amino acid other than tryptophan, threonine and methionine that is, the food or drink containing only tryptophan, threonine and methionine as amino acids is also one embodiment of the present invention.
- Examples thereof include a food intake regulating agent in a unit packaging form for one meal, which generally contains 6 mg-23 g, preferably 10 mg-20 g, more preferably 50 mg-15 g, particularly preferably 60 mg-15 g, of the amino acids of (1)-(4) in total as the amount to be ingested per meal in the unit.
- a food intake regulating agent containing 60 mg-2 g is preferable.
- a food or drink for regulating food intake which is in a unit packaging form for one meal, and contains not less than 0.06 g of 4 kinds of amino acids of tryptophan, threonine, methionine and isoleucine in total in the unit, wherein the weight ratio of tryptophan, threonine, methionine and isoleucine is 1:0.5-12:0.2-10:0.5-12, is also one embodiment of the present invention.
- not more than 5 g, more preferably not more than 3 g, further preferably not more than 2 g, in total of the above-mentioned 4 kinds of amino acids is preferably contained.
- the above-mentioned food or drink which is free of an amino acid other than tryptophan, threonine, methionine and isoleucine that is, the food or drink containing only tryptophan, threonine, methionine and isoleucine as amino acids is also one embodiment of the present invention.
- Examples thereof include a food intake regulating agent in a unit packaging form for one meal, which generally contains 6 mg-23 g, preferably 10 mg-20 g, more preferably 50 mg-15 g, particularly preferably 60 mg-15 g, of the amino acids of (1)-(5) in total as the amount to be ingested per meal in the unit.
- a food or drink for regulating food intake which is in a unit packaging form for one meal, and contains not less than 0.06 g of 5 kinds of amino acids of tryptophan, threonine, methionine, isoleucine and valine in total in the unit, wherein the weight ratio of tryptophan, threonine, methionine, isoleucine and valine is 1:0.5-12:0.2-10:0.5-12:0.5-15, is also one embodiment of the present invention.
- not more than 5 g, more preferably not more than 3 g, further preferably not more than 2 g, in total of the above-mentioned 5 kinds of amino acids is preferably contained.
- the above-mentioned food or drink which is free of an amino acid other than tryptophan, threonine, methionine, isoleucine and valine, that is, the food or drink containing only tryptophan, threonine, methionine, isoleucine and valine as amino acids is also one embodiment of the present invention.
- a unit packaging form for one meal which contains, as one ingestion amount in the unit, generally (1) 1 mg-9 g, (2) 3 mg-20 g, (3) 2 mg-18 g, (4) 0-20 g, (5) 0-20 g, preferably (1) 2 mg-6 g, (2) 6 mg-18 g, (3) 4 mg-15 g, (4) 6 mg-18 g, (5) 10 mg-18 g, more preferably (1) 8 mg-5 g, (2) 25 mg-15 g, (3) 17 mg-12 g, (4) 25 mg-15 g, (5) 40 mg-16 g can be mentioned.
- the above-mentioned numerical values can be set to 10- to 60-fold.
- the weight (%) of each amino acid in the contained amino acids is
- v. tryptophan 0.5%-45% (2) threonine 1.5%-70%, (3) methionine 1.0%-50%, (4) isoleucine 0.001%-50%, preferably (1) 3.5%-40%, (2) 5%-65%, (3) 6%-45%, (4) 0.001%-45%, more preferably (1) 5%-33%, (2) 8%-60%, (3) 10%-40%, (4) 0.001%-40%.
- the nutrition composition shown in Table 1 was formulated, based on which a granular powder product was prepared as the nutrition composition of the present invention. That is, a mixture having the composition of Table 1 was mixed in a compact high speed mixer (NSK-150S, manufactured by OKADA SEIKO CO., LTD.) for 5 min. Thereafter, 2-5 wt % of distilled water was added to the mixture, and the mixture was further kneaded in the mixer for 5 min to give a moist kneaded mixture. The moist kneaded mixture was granulated using an extrusion granulator with a 1.0 mm ⁇ screen, the obtained formed product was dried at 80° C.
- this granular powder nutrition composition could be used by dissolving in warm water and mixing with a nutritional supplement, and could be prepared as an ion drink. Furthermore, it could be further mixed with a spice, salts such as sodium chloride and the like, sodium glutamate, nucleic acid and the like, and added to various foods.
- Example 2 In the same manner as in Example 1 except that a mortar was used instead of the high speed mixer for kneading and a horizontal extruder (manufactured by UMETANI TEKKOUSHO) was used as the extrusion granulator, a granular powder could be obtained.
- the nutrition composition shown in Table 2 was formulated, based on which a jelly nutrition composition was prepared as the nutrition composition of the present invention. That is, thickened polysaccharide and water were added to the composition of Table 2, and the mixture was emulsified by mixing and stirring with heating. After cooling, the emulsion was adjusted to pH 3.8, and sterilized by heating at 80° C. for 10 min. 1.25 g was cooled and filled in a pouch. The whole components of the jelly nutrition composition of this Example were stable even after one year.
- the liquid nutrition composition shown in Table 3 was prepared.
- the amounts of the starting materials of a liquid product for realizing this are shown in Table 3.
- Each component and an emulsifier were mixed with water, and an emulsification step was repeated plural times in a high-pressure emulsifier under pressurization at 500-1,000 kg/cm 2 to give an emulsion composition.
- This emulsion composition was filled in an aluminum bag by a general filling machine, and sterilized by a retort sterilizing machine under general conditions. The whole components of the nutrition composition of this Example were stable even after one year.
- a thickener was added to the prepared solution, whereby a thickened nutrition composition (1,000-7,000 mPa s) or jelly could be produced. Furthermore, similar production was possible even when the amount of the amino acid to be added was 3-fold.
- the caloric density of this nutrition composition was 1.6 kcal/ml.
- the nutrient composition shown in Table 4 was formulated, based on which a corn soup nutrition composition was prepared as the nutrition composition of the present invention.
- the starting materials shown in Table 4 were mixed, and the mixture was fluidized bed granulated to prepare a powdered corn soup (20 g). Furthermore, consomme soup and pumpkin soup could also be produced similarly.
- amino acid total amino acid (A11AA), non-essential amino acid (NEAA), essential amino acid (EAA) or 5 kinds of amino acids (5AA) were added to a 5 wt % casein feed and administered.
- the compositions and amounts of the amino acids are shown in Table 5.
- the composition of the amino acid was constituted based on the amino acid composition of the casein protein, and an amount corresponding to 15 wt % casein was added to the feed.
- the content excluding the amino acid was replaced by cornstarch.
- the food intake amount in 2 weeks after the feed change was measured.
- FIG. 1 shows an average food intake amount per day in 2 weeks after changing the feed. It was found that overeating can be suppressed by adding an amino acid (A11AA) in an amount corresponding to 15% of amino acid in casein composition to a 5 wt % casein feed. While overeating could not be suppressed by adding only non-essential amino acid moiety of the amino acids (NEAA), overeating was suppressed when essential amino acid (EAA) or 5 kinds of amino acids were added (5AA).
- A11AA amino acid
- NEAA non-essential amino acid moiety of the amino acids
- amino acids 5 kinds of amino acids (5AA) or those excluding one or two kinds were added to a 5 wt % casein feed.
- the compositions and amounts of the amino acids are shown in Table 6.
- the composition of the amino acid was constituted based on the amino acid composition of the casein protein, and an amount corresponding to 15 wt % casein was added to the feed.
- the content excluding the amino acid was replaced by cornstarch.
- the food intake amount in 2 weeks after the feed change was measured.
- FIG. 2 shows an average food intake amount per day in 2 weeks after changing the feed. Overeating was suppressed when an amino acid (A11AA) in an amount corresponding to 15% of amino acid in casein composition was added or 5 kinds of amino acids were added (5AA) to a 5 wt % casein feed. Overeating was suppressed even when only one kind of L-valine or L-isoleucine was removed from 5AA. In contrast, when any one kind of L-threonine, L-methionine and L-tryptophan, or two kinds of L-valine and L-isoleucine were removed, suppression of overeating was attenuated.
- L-threonine, L-methionine and L-tryptophan in the 5 kinds of amino acids were essential for a suppressive effect on overeating, and a possibility of maintaining the suppressive effect on overeating even after removing any of L-valine and L-isoleucine was suggested.
- the suppressive effect on overeating was clearly attenuated.
- an administration test of amino acid was performed.
- As the amino acid a mixed aqueous solution of essential amino acid (EAA) or 5 kinds of amino acids (5AA) was administered.
- the compositions and dose of the amino acids are shown in Table 7.
- the composition of the amino acid was constituted based on the amino acid composition of the casein protein, and administered immediately before the dark period which is a mouse active period, and the food intake amount in 2 hours after the administration was measured.
- FIG. 3 shows food intake amounts before administration and 2 hr in the dark period after administration. After administration, a significant increase in the food intake amount was found as compared to that before administration; 145% in the essential amino acid administration group (EAA) and 160% in the 5 kinds of amino acids administration group (5AA). Particularly, the 5 kinds of amino acids administration group showed a significant food intake amount increasing effect even when compared to the essential amino acid administration group.
- EAA essential amino acid administration group
- 5AA 5 kinds of amino acids administration group
- a food consumption decrease model was fed with a test feed, which was prepared by reducing the protein in standard purified feed AIN-93G (manufactured by Oriental Yeast Co., Ltd.) to give a 1 wt % casein feed, and adding 5 kinds of amino acids at a proportion of 0.2 wt %, for 2 weeks, and a blend feed administration test was performed.
- the compositions of 5 kinds of amino acids are similar to those in Table 7.
- the body weight profile in the blend feed test for 2 weeks is shown in FIG. 4
- the food intake amount profile in the dark period is shown in FIG. 5 .
- Both the body weight and food intake amount of the 5AA addition feed group significantly increased after 7 days from the start of the test feed as compared to the 1 wt % casein food group free of amino acid addition.
- the food intake amount profiles for 2 hr in the dark period after 8 days from the start of the blend feed test of 3 examples for each group are shown in FIG. 6 .
- the graph showed a flat shape since the food intake amount per one time is small in the 1 wt % casein food group as compared to that of the 20 wt % casein food group measured at the same date and time after the start of the dark period.
- the shape of the graph became closer to that of the 20 wt % casein food group.
- the meal pattern was analyzed according to the following standard by reference to Neuropsychopharmacology 2003, Vol. 28, pp. 1311-1316.
- MS meal size
- IMI postprandial intermeal interval
- SR satiety ratio
- SR significantly increased in the 1 wt % casein food group and the 5AA group as compared to the 20 wt % casein food group.
- SR of the 5AA group decreased after the start of the blend feed test.
- the body weight and each organ weight after 2 weeks from the blend feed test are shown in FIG. 8 . It was shown that all of body weight, liver weight, epididymis fat weight and gastrocnemius muscle weight decreased in the 1 wt % casein food group as compared to those of the 20 wt % casein food group, and were recovered in the 5AA group.
- the granules in an amount corresponding to 1 g of a total amount of amino acids were ingested by ten elderly people (2 males, 8 females, average age 79.7 ⁇ 7.7 years old) once per day for 2 months. Inquiring survey of food ingestion frequency and incentive to having a meal before and after the start of amino acid granule ingestion, and meal intake amount and the contents of the meal, and the measurement of body weight were compared.
- the inquiry used for food ingestion frequency search constituted of 44 questions (in-between snacks, principal food, potatoes, fruits, hypochromic vegetable, deep yellow vegetables, seaweeds, mushrooms, pickles, tofu, nattou, sesami, meat (liver, processed food), fish and shellfish (fish, squid, shrimp, octopus, fishery paste product), chicken egg, milk, cheese, yoghurt, butter ⁇ margarine, dressing ⁇ mayonnaise, salt-preserved product, deep-fried food, fried food, cooked food, soup, alcohol).
- the ingested nutrient amounts converted from the results of the food ingestion frequency search before and after the start of amino acid granule ingestion are shown in Table 9.
- the ingested amounts of energy, protein, lipid, vitamin D significantly increased after the amino acid granule ingestion.
- the items of inquiry used for food ingestion frequency search are divided into 6 food groups and shown in Table 10.
- the body weights before and after the start of amino acid granule ingestion are shown in Table 14. As a result of comparison between before and after the start of amino acid granule ingestion, a significant increase in the body weight was observed after the amino acid granule ingestion.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Non-Alcoholic Beverages (AREA)
- Seeds, Soups, And Other Foods (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
BMI=body weight (kg)÷body height (m)÷body height (m)
less than 18.5 thin
18.5—less than 25 normal
25—obese
TABLE 1 | ||
unit | wt % (weight ratio) | |
L-tryptophan | % | 6 | (1.0) | ||
L-threonine | % | 17 | (2.8) | ||
L-methionine | % | 12 | (2.0) | ||
L-isoleucine | % | 18 | (3.0) | ||
L-valine | % | 27 | (4.5) | ||
| % | 12 | |||
| % | 8 | |||
| % | 100 | |||
TABLE 2 | |||
unit | wt % (weight ratio) | wt % (weight ratio) | |
L-tryptophan | % | 6 | (1.0) | 10 | (1.0) | |
L-threonine | % | 17 | (2.8) | 30 | (3.0) | |
L-methionine | % | 12 | (2.0) | 19 | (1.9) | |
L-isoleucine | % | 18 | (3.0) | 22 | (2.2) | |
L-valine | % | 27 | (4.5) | 0 | ||
| % | 12 | 12 | |||
| % | 8 | 7 | |||
| % | 100 | 100 | |||
TABLE 3 |
50 mL (80 kcal)/pack |
component | unit | content/pack (weight ratio) |
protein | g | 0.9 |
L-tryptophan | g | 0.07 (1.0) |
L-threonine | g | 0.20 (2.9) |
L-methionine | g | 0.13 (1.9) |
L-isoleucine | g | 0.21 (3.0) |
L-valine | g | 0.30 (4.3) |
lipid | g | 4.8 |
middle chain fatty acid | g | 0.7 |
hydrocarbonate | g | 14.7 |
carbohydrates | g | 13.2 |
dietary fiber | g | 1.5 |
sodium | mg | 88.3 |
calcium | mg | 35.8 |
iron | mg | 1.7 |
phosphorus | mg | 34.6 |
magnesium | mg | 16.6 |
potassium | mg | 101.8 |
copper | mg | 0.01 |
iodine | μg | 6.4 |
selenium | μg | 0.9 |
zinc | mg | 1.9 |
vitamin A | μg RE *1 | 76.8 |
vitamin D | μg | 0.3 |
vitamin E | mg α-TE *2 | 3.4 |
vitamin K | μg | 7.0 |
vitamin B1 | mg | 0.1 |
vitamin B2 | mg | 0.1 |
niacin | mg NE *3 | 1.2 |
vitamin B6 | mg | 0.3 |
folic acid | μg | 25.6 |
vitamin B12 | μg | 0.5 |
pantothenic acid | mg | 1.0 |
vitamin C | mg | 8.3 |
*1: retinol equivalent | ||
*2: α-tocopherol reduced quantity | ||
*3: niacin equivalent |
TABLE 4 | |||
unit | wt % (weight ratio) | wt % (weight ratio) | |
L-tryptophan | % | 0.5 | (1.0) | 2.2 | (1.0) |
L-threonine | % | 1.0 | (2.0) | 6.0 | (2.7) |
L-methionine | % | 0.9 | (1.8) | 4.8 | (2.2) |
L-isoleucine | % | 1.0 | (2.0) | 5.4 | (2.4) |
L-valine | % | 1.5 | (3.0) | 0.0 | |
corn powder | % | 29.4 | 20.2 | ||
potato starch | % | 20.6 | 15.0 | ||
crushed sugar | % | 7.8 | 7.8 | ||
pulverized sodium | % | 3.6 | 4.9 | ||
glutamate | |||||
pulverized sodium | % | 8.2 | 8.2 | ||
chloride | |||||
non-fat dried milk | % | 6.9 | 6.9 | ||
fat and oil powder | % | 8.8 | 8.8 | ||
lactose | % | 9.8 | 9.8 | ||
| % | 100 | 100 | ||
TABLE 5 |
amino acid composition (wt % to total amino |
acid) and amino acid amount per 1 kg feed |
weight | ||||||
unit | AIIAA | NEAA | EAA | 5AA | ratio | |
L-tryptophan | % | 1.2 | 2.4 | 6.2 | 1.0 | |
L-threonine | % | 4.1 | 8.5 | 21.7 | 3.5 | |
L-methionine | % | 2.6 | 5.4 | 13.9 | 2.2 | |
L-isoleucine | % | 4.7 | 9.9 | 25.4 | 4.1 | |
L-valine | % | 6.1 | 12.8 | 32.8 | 5.3 | |
L-leucine | % | 8.7 | 18.2 | |||
L-lysine hydrochloride | % | 9.4 | 19.7 | |||
L-phenylalanine | % | 4.8 | 10.1 | |||
L-histidine | % | 2.7 | 5.7 | |||
L-arginine | % | 3.5 | 7.3 | |||
L-alanine | % | 2.7 | 5.2 | |||
L-asparagine | % | 3.8 | 7.3 | |||
monohydrate | ||||||
L-aspartic acid | % | 3.4 | 6.5 | |||
L-cystine | % | 0.5 | 1.0 | |||
L-glutamine | % | 9.8 | 18.7 | |||
L-glutamic acid | % | 9.8 | 18.7 | |||
L-glycine | % | 1.7 | 3.3 | |||
L-proline | % | 10.0 | 19.1 | |||
L-serine | % | 5.4 | 10.3 | |||
L-tyrosine | % | 5.1 | 9.9 | |||
amount of total | g/kg | 140.7 | 73.6 | 67.2 | 26.3 | |
amino acid (g/kg) | ||||||
TABLE 6 |
amino acid composition (wt % to total amino |
acid) and amount of amino acid per 1 kg feed |
weight | ||||||||
unit | MVIW | TVIW | TMVI | TMIW | TMVW | TMW | ratio | |
L-tryptophan | % | 7.9 | 7.2 | 9.2 | 8.3 | 14.8 | 1 | |
L-threonine | % | 25.3 | 23.2 | 32.3 | 29.2 | 52.0 | 3.5 | |
L-methionine | % | 17.8 | 14.8 | 20.7 | 18.6 | 33.2 | 2.2 | |
L-isoleucine | % | 32.5 | 29.5 | 27.1 | 37.8 | 4.1 | ||
L-valine | % | 41.8 | 38.0 | 34.9 | 43.9 | 5.3 | ||
amount of total | g/kg | 20.5 | 22.6 | 24.6 | 17.7 | 19.6 | 11.0 | |
amino acid (g/kg) | ||||||||
TABLE 7 |
amino acid composition (wt % to total amino acid) and dose |
unit | EAA | 5AA | weight ratio | |
L-tryptophan | % | 3.2 | 7.3 | 1.0 |
L-threonine | % | 9.3 | 21.5 | 2.9 |
L-methionine | % | 6.4 | 14.7 | 2.0 |
L-isoleucine | % | 10.0 | 23.0 | 3.1 |
L-valine | % | 14.5 | 33.5 | 4.6 |
L-leucine | % | 20.9 | ||
L-lysine hydrochloride | % | 17.3 | ||
L-phenylalanine | % | 11.4 | ||
L-histidine | % | 7.0 | ||
dose (g/kg BW) | g/kg BW | 0.30 | 0.13 | |
TABLE 8 | ||
unit | wt % (weight ratio) | |
L-tryptophan | % | 10.46 | (1.0) | |
L-threonine | % | 30.70 | (2.9) | |
L-threonine | % | 21.01 | (2.0) | |
L-isoleucine | % | 32.89 | (3.1) | |
sucrose fatty acid ester | % | 2.85 | ||
flavor preparation | % | 0.95 | ||
lecithin | % | 1.14 |
99.5% alcohol | — | |
distilled water | — |
the total amount | % | 100.00 | ||
TABLE 9 |
comparison of ingested nutrient amounts before |
and after amino |
2 months after | |||
before ingestion | ingestion | ||
mean ± S.D. | mean ± S.D. | p value | |
energy (kcal) | 1591 ± 224.0 | 1764 ± 321.6 | 0.017* |
protein (g) | 57.5 ± 8.5 | 66.4 ± 11.9 | 0.018* |
lipid (g) | 47.4 ± 12.7 | 59.4 ± 19.2 | 0.003* |
hydrocarbonate (g) | 237.0 ± 31.9 | 241.8 ± 45.9 | 0.699 |
calcium (mg) | 644 ± 152.7 | 639 ± 156.5 | 0.938 |
iron (mg) | 11.8 ± 3.3 | 11.8 ± 3.4 | 0.972 |
vitamin A (mg) | 1620 ± 503.8 | 1733 ± 827.7 | 0.688 |
vitamin B1 (mg) | 1.05 ± 0.2 | 1.14 ± 0.3 | 0.217 |
vitamin B2 (mg) | 1.26 ± 0.3 | 1.41 ± 0.3 | 0.121 |
vitamin C (mg) | 213 ± 41.5 | 204 ± 79.2 | 0.612 |
vitamin D (μg) | 5.3 ± 2.6 | 8.0 ± 2.8 | 0.007* |
dietary fiber (g) | 22.5 ± 6.0 | 21.0 ± 6.2 | 0.456 |
salt content (g) | 10.3 ± 1.7 | 10.3 ± 1.6 | 0.972 |
TABLE 10 |
6 basic foods |
food group | |
|
1 | fish/meat | protein source |
egg | ||
bean/ |
||
2 | milk/milk product | calcium source |
seaweed | ||
|
||
3 | deep yellow vegetables | vitamin A source |
4 | other vegetables | vitamin |
fruit | ||
5 | grains | carbohydrate energy source |
potatoes | ||
saccharides | ||
6 | fats and oils | fat energy source |
TABLE 11 |
comparison of ingestion frequency of 6 food groups |
before and after amino |
2 months after | |||
before ingestion | ingestion | ||
mean ± S.D. | mean ± S.D. | | |
group |
1 | 3.4 ± 1.2 | 3.9 ± 1.2 | 0.002* | |
|
3.7 ± 1.5 | 3.7 ± 1.5 | 0.870 | |
|
2.7 ± 1.3 | 2.8 ± 1.2 | 0.840 | |
group 4 | 2.7 ± 1.3 | 2.6 ± 1.3 | 0.660 | |
|
3.0 ± 0.7 | 2.9 ± 1.0 | 0.730 | |
group 6 | 3.9 ± 1.6 | 4.0 ± 1.3 | 0.680 | |
TABLE 12 |
comparison of meal intake amount before and |
after amino |
2 months after | |||
before ingestion | ingestion | ||
category of meal (g) | mean ± S.D. | mean ± S.D. | p value |
principal food | 149 ± 34.7 | 141 ± 36.2 | 0.051 |
main dish | 145 ± 39.6 | 194 ± 42.7 | 0.003* |
side dish(1) | 44 ± 7.8 | 65 ± 30.5 | 0.070 |
side dish(2) | 78 ± 41.7 | 85 ± 44.9 | 0.580 |
side dish(3) | 50 ± 11.5 | 52 ± 31.1 | 0.820 |
TABLE 13 |
comparison of manners of taking meals |
before and after amino acid granule intake |
before | 2 months | |
intake | after intake |
mean ± | mean ± | P | ||||
item | n | S.D. | n | S.D. | value | |
incentive | eat willingly | 4 | 2.4 ± 0.5 | 9 | 2.9 ± 0.3 | 0.015* |
for | eat when | 6 | 1 | |||
meal | prompted | |||||
no |
0 | 0 | ||||
to eat | ||||||
content | eat in well- | 8 | 10 | |||
of | balanced manner | |||||
meal | avoid particular | 1 | 2.4 ± 0.8 | 0 | 3.0 ± 0.0 | 0.096 |
food | ||||||
concentrated on | 2 | 0 | ||||
eating one dish | ||||||
TABLE 14 |
comparison of body weight before and after |
amino |
2 months after | |||
before ingestion | ingestion | ||
mean ± S.D. | mean ± S.D. | p value | |
age (years old) | 79.7 ± 7.7 | — | — |
body weight (kg) | 45.0 ± 6.6 | 46.0 ± 6.9 | 0.027* |
Claims (14)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013-036436 | 2013-02-26 | ||
JP2013036436 | 2013-02-26 | ||
PCT/JP2014/054644 WO2014132985A1 (en) | 2013-02-26 | 2014-02-26 | Nutrition composition |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2014/054644 Continuation WO2014132985A1 (en) | 2013-02-26 | 2014-02-26 | Nutrition composition |
Publications (2)
Publication Number | Publication Date |
---|---|
US20150359252A1 US20150359252A1 (en) | 2015-12-17 |
US10765663B2 true US10765663B2 (en) | 2020-09-08 |
Family
ID=51428248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/834,880 Active US10765663B2 (en) | 2013-02-26 | 2015-08-25 | Nutrition composition |
Country Status (5)
Country | Link |
---|---|
US (1) | US10765663B2 (en) |
EP (1) | EP2977047B1 (en) |
JP (2) | JP6555122B2 (en) |
CN (2) | CN113491334B (en) |
WO (1) | WO2014132985A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6551393B2 (en) * | 2014-03-07 | 2019-07-31 | 味の素株式会社 | Weak preventive agent |
Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3697287A (en) * | 1969-01-28 | 1972-10-10 | Morton Norwich Products Inc | Amino acid food composition |
US4009265A (en) | 1972-03-06 | 1977-02-22 | Alan Norman Howard | Methods and formulations for the treatment of obesity |
JPS63502558A (en) | 1986-02-08 | 1988-09-29 | ザ ハワ−ド ファウンデ−ション | Sweet confectionery products and their manufacturing methods |
US5132113A (en) | 1990-10-26 | 1992-07-21 | Maurizio Luca | Nutritional composition containing essential amino acids |
US5242697A (en) * | 1990-10-26 | 1993-09-07 | Maurizio Luca | Method of preparing nutrified food products |
JPH0624977A (en) | 1992-07-10 | 1994-02-01 | Rikagaku Kenkyusho | Antiobestic agent and antilipidemic agent |
JPH0920678A (en) | 1995-06-06 | 1997-01-21 | Clintec Nutrition Co | Composition and method for medical treatment for weakening of kidney |
JPH0952828A (en) | 1995-08-10 | 1997-02-25 | Sasaki Kagaku Kogyo Kk | Amino acid composition and its use |
JPH09157163A (en) | 1995-12-06 | 1997-06-17 | Sasaki Kagaku Kogyo Kk | Amino acid composition and its ingestion |
JPH1028553A (en) | 1996-07-11 | 1998-02-03 | Morinaga Milk Ind Co Ltd | Immunoactivation liquid food |
JPH11508282A (en) | 1996-04-25 | 1999-07-21 | アボツト・ラボラトリーズ | Methods for preventing and treating cachexia and anorexia |
EP1121865A2 (en) | 1999-11-04 | 2001-08-08 | Vitaflo Limited | A medical composition for the treatment and/or prevention of malnutrition |
WO2004026294A1 (en) | 2002-09-20 | 2004-04-01 | Novartis Ag | Leucine-enriched nutritional compositions |
US20040171690A1 (en) | 2001-04-26 | 2004-09-02 | Patrick Ammann | Use of protein essential aminoacids to treat amenorrhea and related disorders |
JP2006022072A (en) | 2004-07-09 | 2006-01-26 | Atsuyoshi Murakami | Appetite control agent |
WO2006070873A1 (en) | 2004-12-28 | 2006-07-06 | Ajinomoto Co., Inc. | Adiponectin inducer or secretagogue |
JP2007197363A (en) | 2006-01-26 | 2007-08-09 | Beta Shokuhin Kk | Nutritional supplement |
WO2009143937A1 (en) * | 2008-04-16 | 2009-12-03 | Italfarmacia Srl | Compositions for protein-based dietary products |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2657013B1 (en) * | 1990-01-18 | 1992-05-15 | Medgenix Group Sa | DIETETIC COMPOSITION BASED ON POLYPEPTIDES AND AMINO ACIDS. |
-
2014
- 2014-02-26 CN CN202110606999.4A patent/CN113491334B/en active Active
- 2014-02-26 EP EP14757392.7A patent/EP2977047B1/en active Active
- 2014-02-26 JP JP2015502946A patent/JP6555122B2/en active Active
- 2014-02-26 WO PCT/JP2014/054644 patent/WO2014132985A1/en active Application Filing
- 2014-02-26 CN CN201480023536.3A patent/CN105120857B/en active Active
-
2015
- 2015-08-25 US US14/834,880 patent/US10765663B2/en active Active
-
2019
- 2019-03-04 JP JP2019038192A patent/JP2019108364A/en active Pending
Patent Citations (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3697287A (en) * | 1969-01-28 | 1972-10-10 | Morton Norwich Products Inc | Amino acid food composition |
US4009265A (en) | 1972-03-06 | 1977-02-22 | Alan Norman Howard | Methods and formulations for the treatment of obesity |
JPS63502558A (en) | 1986-02-08 | 1988-09-29 | ザ ハワ−ド ファウンデ−ション | Sweet confectionery products and their manufacturing methods |
US4900566A (en) | 1986-02-08 | 1990-02-13 | The Howard Foundation | Confectionary product and a process for producing the same |
US5132113A (en) | 1990-10-26 | 1992-07-21 | Maurizio Luca | Nutritional composition containing essential amino acids |
JPH04346770A (en) | 1990-10-26 | 1992-12-02 | Maurizio Luca | Nutrition supply composition |
US5242697A (en) * | 1990-10-26 | 1993-09-07 | Maurizio Luca | Method of preparing nutrified food products |
JPH0624977A (en) | 1992-07-10 | 1994-02-01 | Rikagaku Kenkyusho | Antiobestic agent and antilipidemic agent |
US5728678A (en) | 1995-06-06 | 1998-03-17 | Nestec Ltd. | Method and composition for providing nutrition to a renal failure patient |
JPH0920678A (en) | 1995-06-06 | 1997-01-21 | Clintec Nutrition Co | Composition and method for medical treatment for weakening of kidney |
JPH0952828A (en) | 1995-08-10 | 1997-02-25 | Sasaki Kagaku Kogyo Kk | Amino acid composition and its use |
JPH09157163A (en) | 1995-12-06 | 1997-06-17 | Sasaki Kagaku Kogyo Kk | Amino acid composition and its ingestion |
US6077828A (en) | 1996-04-25 | 2000-06-20 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
US20040167081A1 (en) | 1996-04-25 | 2004-08-26 | Abbruzzese Bonnie Chandler | Method for the prevention and treatment of cachexia and anorexia |
US20070196445A1 (en) | 1996-04-25 | 2007-08-23 | Abbruzzese Bonnie C | Method for the Prevention and Treatment of Cachexia and Anorexia |
JPH11508282A (en) | 1996-04-25 | 1999-07-21 | アボツト・ラボラトリーズ | Methods for preventing and treating cachexia and anorexia |
US6326355B1 (en) | 1996-04-25 | 2001-12-04 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
US6387883B1 (en) | 1996-04-25 | 2002-05-14 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
US20020099020A1 (en) | 1996-04-25 | 2002-07-25 | Abbruzzese Bonnie Chandler | Method for the prevention and treatment of cachexia and anorexia |
JPH1028553A (en) | 1996-07-11 | 1998-02-03 | Morinaga Milk Ind Co Ltd | Immunoactivation liquid food |
EP1121865A2 (en) | 1999-11-04 | 2001-08-08 | Vitaflo Limited | A medical composition for the treatment and/or prevention of malnutrition |
US20040171690A1 (en) | 2001-04-26 | 2004-09-02 | Patrick Ammann | Use of protein essential aminoacids to treat amenorrhea and related disorders |
JP2005505500A (en) | 2001-04-26 | 2005-02-24 | ノバルテイス・ニユートリシヨン・アクチエンゲゼルシヤフト | Use of proteins and essential amino acids to treat amenorrhea and related diseases |
WO2004026294A1 (en) | 2002-09-20 | 2004-04-01 | Novartis Ag | Leucine-enriched nutritional compositions |
US20040087490A1 (en) | 2002-09-20 | 2004-05-06 | Troup John P. | Nutritional compositions |
US20130090297A1 (en) | 2002-09-20 | 2013-04-11 | Nestec S.A. | Nutritional compositions |
JP2006022072A (en) | 2004-07-09 | 2006-01-26 | Atsuyoshi Murakami | Appetite control agent |
WO2006070873A1 (en) | 2004-12-28 | 2006-07-06 | Ajinomoto Co., Inc. | Adiponectin inducer or secretagogue |
US20090012168A1 (en) | 2004-12-28 | 2009-01-08 | Ajinomoto Co., Inc. | Adiponection inducers or secretagogues |
JP2007197363A (en) | 2006-01-26 | 2007-08-09 | Beta Shokuhin Kk | Nutritional supplement |
WO2009143937A1 (en) * | 2008-04-16 | 2009-12-03 | Italfarmacia Srl | Compositions for protein-based dietary products |
Non-Patent Citations (9)
Title |
---|
Acar., N., et al., "Appetite Suppressant Activity of Supplemental Dietary Amino Acids and Subsequent Compensatory Growth of Broilers," Poult. Sci. 2001;80(8):1215-1222 Abstract, Figure 1. |
Communication Pursuant to Article 94(3) EPC from European Patent App. No. 14757392.7 (Jul. 8, 2020). |
Edmonds, M. S., et al., "Amino Acid Excesses for Young Pigs: Effects of Excess Methionine, Tryptophan, Threonine or Leucine," J. Anim. Sci. 1987;64:1664-1671. |
English language International Preliminary Report on Patentability for PCT Patent App. No. PCT/JP2014/054644 (dated Sep. 1, 2015). |
English translation of Notification of Reasons for Refusal from Japanese Patent App. No. 2015-502946 (dated Mar. 6, 2018). |
Marx, J., "Cellular Warriors at the Battle of the Bulge," Science 2003;299(5608):846-849. |
Search Report for European Patent App. No. 14757392.7 (dated Jul. 6, 2016). |
Thomas, D. R., "Use of Orexigenic Medications in Geriatric Patients," Am. J. Geriatric Pharmacotherapy, Excerpta Medica, 2011, vol. 9, No. 2, pp. 97-108. |
Valerio et al., Branched-chain amino acids, mitochondrial biogenesis, and healthspan: an evolutionary perspective., 2011, Aging, vol. 3, No. 5, pp. 464-478. * |
Also Published As
Publication number | Publication date |
---|---|
US20150359252A1 (en) | 2015-12-17 |
JP6555122B2 (en) | 2019-08-07 |
JP2019108364A (en) | 2019-07-04 |
EP2977047A1 (en) | 2016-01-27 |
JPWO2014132985A1 (en) | 2017-02-02 |
CN113491334B (en) | 2023-11-07 |
CN105120857B (en) | 2021-05-14 |
CN113491334A (en) | 2021-10-12 |
WO2014132985A1 (en) | 2014-09-04 |
CN105120857A (en) | 2015-12-02 |
EP2977047A4 (en) | 2016-08-03 |
EP2977047B1 (en) | 2022-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5983601B2 (en) | Nutritional composition | |
CA2689982A1 (en) | Compositions and approaches for increasing diet induced thermogenesis, inducing weight loss and maintaining muscle mass and strength | |
EP3115047B1 (en) | Debility preventative | |
US9480668B2 (en) | Blood flow promoting agent | |
JP6160832B2 (en) | Cysteine and food intake | |
EP3135281B1 (en) | Composition for preventing or improving peripheral neuropathy | |
US11730713B2 (en) | Composition for preventing or improving nociceptive pain | |
EP3900718A1 (en) | Agent for improving muscle quality | |
US10765663B2 (en) | Nutrition composition | |
WO2018079573A1 (en) | Composition for improving decreased absorption in digestive tract, and composition for promoting absorption in digestive tract | |
WO2021193820A1 (en) | Composition for promoting hair thickening, composition for sustaining growth phase in hair cycle and composition for promoting vegf production, composition for promoting transition from resting phase to growth phase in hair cycle and composition for promoting fgf7 production, and composition for promoting hair cycle normalization | |
JP6159382B2 (en) | Oral UV resistance improver | |
WO2021112217A1 (en) | Composition for suppressing increase in amount of neutral fat in liver | |
US20240082299A1 (en) | Composition for improving or preventing iron deficiency anaemia | |
WO2022244867A1 (en) | Composition for improving cognitive function, agent for improving cognitive function, and food for improving cognitive function | |
JP2021087408A (en) | Composition for reducing amounts of enteric deoxycholic acid | |
JP2019151599A (en) | Composition for improving anxiety-like behavior | |
JP2020033269A (en) | Brain function improving composition | |
JP2019058140A (en) | Nutritional composition | |
JP2013170158A (en) | Oral ultraviolet light resistance improver |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: AJINOMOTO CO., INC., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HAMADA, MIKA;NAGAO, KENJI;SEKI, ASUKA;SIGNING DATES FROM 20151109 TO 20151209;REEL/FRAME:037343/0152 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |